Secukinumab Provides Clinical Benefit for JIA Subtypes Secukinumab Provides Clinical Benefit for JIA Subtypes
Phase 3 trial shows secukinumab is effective for enthesitis-related arthritis and juvenile psoriatic arthritis in children.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - June 16, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Arthritis symptoms: Four 'weird and unusual' signs of arthritis pain you might be missing
ARTHRITIS symptoms usually include joint pain and inflammation, but the signs could also be more subtle. These are the four most common "weird and unusual" symptoms of psoriatic arthritis that you might be missing - should you speak to a doctor? (Source: Daily Express - Health)
Source: Daily Express - Health - June 16, 2021 Category: Consumer Health News Source Type: news

What Does a Psoriatic Arthritis Rash Look Like
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Are the Five Types of Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 10, 2021 Category: General Medicine Source Type: news

What Foods Make Psoriatic Arthritis Worse
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 8, 2021 Category: General Medicine Source Type: news

What Is the Best Treatment for Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 7, 2021 Category: General Medicine Source Type: news

New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fecal Transplantation Safe but Ineffective in PsA Trial Fecal Transplantation Safe but Ineffective in PsA Trial
A trial found fecal microbiota transplantation in psoriatic arthritis inferior to sham but safe, and investigators said it's worthy of future study.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 8, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

What Can Mimic Psoriatic Arthritis
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 20, 2021 Category: General Medicine Source Type: news

Arthritis symptoms: Nail changes are a ‘strong predictor’ of arthritis - what to look for
Arthritis is a common condition that causes pain and inflammation in a joint. Arthritis comes in many forms and nail changes are predictive of a type of arthritis called psoriatic arthritis. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2021 Category: Consumer Health News Source Type: news

Will Psoriatic Arthritis Cripple Me?
Title: Will Psoriatic Arthritis Cripple Me?Category: Diseases and ConditionsCreated: 4/5/2021 12:00:00 AMLast Editorial Review: 4/5/2021 12:00:00 AM (Source: MedicineNet Arthritis General)
Source: MedicineNet Arthritis General - April 5, 2021 Category: Rheumatology Source Type: news

Upadacitinib Beats Placebo for Psoriatic Arthritis
WEDNESDAY, March 31, 2021 -- For patients with psoriatic arthritis, upadacitinib at a dose of 15 mg or 30 mg once daily is more effective than placebo, according to a study published in the April 1 issue of the New England Journal of Medicine. Iain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 31, 2021 Category: Pharmaceuticals Source Type: news

Experts Highlight Recent Breakthroughs in Psoriatic Arthritis Experts Highlight Recent Breakthroughs in Psoriatic Arthritis
An analysis by Alexis R. Ogdie, MD, of apremilast data from the CORRONA Registry was among several recent highlights in psoriatic arthritis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 31, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Yes or No: The Future of Rheumatology Is Sub-Subspecialization Yes or No: The Future of Rheumatology Is Sub-Subspecialization
It makes little sense for some rheumatologists to declare they're only going to see patients with psoriatic arthritis, or gout, or lupus.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

New Phase 3 Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years
SPRING HOUSE, PENNSYLVANIA, March 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis...
Source: Johnson and Johnson - March 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients Hepatotoxicity Risk Differs Between Psoriasis, PsA, and RA Patients
Patients taking methotrexate for psoriasis or psoriatic arthritis were at a higher risk of developing liver disease than were patients with rheumatoid arthritis on methotrexate.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - February 26, 2021 Category: Rheumatology Tags: Rheumatology News Source Type: news

Treatment Persistence of Biologics in Psoriatic Arthritis Treatment Persistence of Biologics in Psoriatic Arthritis
A better understanding of biologic treatment persistence in psoriatic arthritis patients could help guide treatment decisions.Arthritis Research & Therapy (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 25, 2021 Category: Orthopaedics Tags: Rheumatology Journal Article Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Cardiorespiratory Fitness Linked to Psoriasis, Psoriatic Arthritis
FRIDAY, Jan. 15, 2021 -- Low cardiovascular fitness in late adolescence is associated with an increased risk for incident psoriasis and psoriatic arthritis among men, according to a study published online Jan. 11 in PLOS ONE. Marta Laskowski, from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Osteoporosis Prevalence in PsA Similar to General Population Osteoporosis Prevalence in PsA Similar to General Population
Previous research suggested a possible link between psoriatic arthritis and osteoporosis or osteopenia. However, no cohort studies appear to have examined this association.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 7, 2021 Category: Primary Care Tags: Rheumatology News Source Type: news

Skin Gene Expression May Explain PsA Treatment Responses Skin Gene Expression May Explain PsA Treatment Responses
Differences in gene expression between the skin and synovial tissues of people with psoriatic arthritis could explain why treatments targeting proinflammatory mechanisms don't improve joint symptoms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - December 15, 2020 Category: Internal Medicine Tags: Rheumatology News Source Type: news

CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Across pivotal clinical trial programs, RINVOQ (15 mg, once daily) demonstrated efficacy across multiple measures of disease activity in psoriatic arthritis (PsA) and ankylosing spondylitis (AS), with a safety profile consistent with that seen in rheumatoi... Biopharmaceuticals, Regulatory AbbVie, RINVOQ, upadacitinib, psoriatic arthritis, ankylosing spondylitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 11, 2020 Category: Pharmaceuticals Source Type: news

ACR Convergence: Psoriatic Arthritis ACR Convergence: Psoriatic Arthritis
Dr Saakshi Khattri reviews key abstracts about psoriatic arthritis from the annual ACR meeting, including a tool for early detection and a study showing dactylitis may signal an aggressive phenotype.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Increased falls risk in people with psoriatic arthritis-related foot problems: a novel finding - Carter K, Walmsley S, Oliffe M, Hassett G, Turner ADE.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - November 23, 2020 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Tofacitinib Effective for Ankylosing Spondylitis in Phase 3 Tofacitinib Effective for Ankylosing Spondylitis in Phase 3
The oral JAK inhibitor was significantly more effective than placebo at primary and secondary endpoints. Safety risks were comparable to those seen in the treatment of rheumatoid and psoriatic arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Ixekizumab Treatment of Biologic-Naive Psoriatic Arthritis Ixekizumab Treatment of Biologic-Naive Psoriatic Arthritis
Is ixekizumab a safe and effective therapeutic option for psoriatic arthritis patients naive to biologic treatment?Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 2, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

What Causes Joint Pain?
DiscussionMusculoskeletal problems are common problems in pediatric practice with up to 15% of acute care visits being for this problem. Joint pain is a common concern for families but the differential diagnosis is extensive and needs thoughtful consideration. History is a key to discerning the potential diagnosis but also in guiding the physical examination and laboratory examination. Family history especially for systemic diseases should be considered. On physical examination all joints should be examined include sacroiliac and temporomandibular joints. Is this arthritis or arthralgia? Distinction between inflammatory...
Source: PediatricEducation.org - October 26, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Johnson & Johnson Reports 2020 Third-Quarter Results
New Brunswick, N.J. (October 13, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2020. “Our third-quarter results reflect solid performance and positive trends across Johnson & Johnson, powered by better-than-expected procedure recovery in Medical Devices, growth in Consumer Health, and continued strength in Pharmaceuticals,” said Alex Gorsky, Chairman and Chief Executive Officer. “I am proud of the relentless passion and Credo-led commitment to patients and customers that our colleagues around the world continue to demonstrate as we boldly fight the COVID-19 ...
Source: Johnson and Johnson - October 13, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Experts Assess Infection Risks for Patients on Biologics Experts Assess Infection Risks for Patients on Biologics
A group of experts have summarized and made recommendations about recent findings regarding infections that can occur during treatment for rheumatoid arthritis and psoriatic arthritis.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 8, 2020 Category: Infectious Diseases Tags: Rheumatology News Source Type: news

Pregnancy Studies on Psoriasis, PsA Medications Pick Up Pregnancy Studies on Psoriasis, PsA Medications Pick Up
Pregnancy outcomes data are increasingly emerging but dermatologists, rheumatologists, and their female patients with psoriasis and psoriatic arthritis (PsA) want much more.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - October 2, 2020 Category: Dermatology Tags: Ob/Gyn & Women ' s Health News Source Type: news

SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Glo...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news

Simponi Aria (golimumab) Approved by the FDA for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Simponi Aria (golimumab) for patients 2 years of age and older for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 30, 2020 Category: Drugs & Pharmacology Source Type: news

Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Key discovery in psoriatic arthritis points way for developing targeted treatments
(University of Oxford) The strongest evidence yet of a single cause for psoriatic arthritis has been discovered by researchers. The disease may be activated by the same trigger in different patients which, if identified, could move towards creating therapies that would prevent psoriatic arthritis, and potentially providing a cure. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2020 Category: International Medicine & Public Health Source Type: news

The Long Road to a PsA Prevention Trial The Long Road to a PsA Prevention Trial
About one third of all patients with psoriasis will develop psoriatic arthritis in their lifetime. With no definitive blood test for diagnosis, prevention trials are key to identifying high-risk groups.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 5, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Ixekizumab in psoriatic arthritis: more QALYs, lower cost in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 31, 2020 Category: Drugs & Pharmacology Source Type: news

Tumor Necrosis Factor Alpha Inhibitors May Pose Risk in Ankylosing Spondylitis and Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - August 21, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis FDA Approves Tremfya (Guselkumab) for Psoriatic Arthritis
Guselkumab, first approved for adults with plaque psoriasis in 2017, has now been approved for adults with active psoriatic arthritis (PsA). The FDA based its approval on two pivotal phase 3 trials.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - July 15, 2020 Category: Dermatology Tags: Rheumatology News Source Type: news

TREMFYA ® (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for adult patients with active psoriatic arthritis (PsA), a chronic progressive disease characterized by painful joints and skin inflammation.[1],[2] TREMFYA is the first treatment approved for active PsA that selectively inhibits interleukin (IL)-23, a naturally occurring cytokine that is involved in normal inflammatory and immune responses associated with the symptoms of PsA. The safety and efficacy of TREMFYA in PsA have b...
Source: Johnson and Johnson - July 14, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
In two Phase 3 clinical trials, TREMFYA significantly improved signs and symptoms in joints, skin and soft tissue in adults with active psoriatic arthritis TREMFYA is the first and only biologic approved for the treatment of active psoriatic arthritis t... Biopharmaceuticals, FDA Janssen Pharmaceutical, Johnson & Johnson, TREMFYA, guselkumab, PsA (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 14, 2020 Category: Pharmaceuticals Source Type: news

Tremfya (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
HORSHAM, PA, July 14, 2020– The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for adult patients with active psoriatic arthritis... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 14, 2020 Category: Drugs & Pharmacology Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA TNF Inhibitor Plus Methotrexate Surpassed Monotherapy in PsA
The addition of a TNF inhibitor to the treatment regimen of patients with psoriatic arthritis (PsA) improves the achievement of minimal disease activity, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 10, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Upadacitinib Looks Effective for Psoriatic Arthritis Upadacitinib Looks Effective for Psoriatic Arthritis
Findings from a pair of phase 3 trials support use of the JAK inhibitor for psoriatic arthritis; it has already been approved for rheumatoid arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 9, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

BIOCAD presents results of clinical trial proving efficacy of netakimab at EULAR 2020
(BIOCAD) BIOCAD presents results of clinical trial proving efficacy of netakimab in the treatment of psoriatic arthritis at the Annual European Congress of Rheumatology (EULAR 2020). Four abstracts present the results from an international randomized double-blind phase 3 clinical trial (PATERA) which demonstrate netakimab decreases disease activity and reduces skin manifestation of psoriatic arthritis through 24 weeks of therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2020 Category: International Medicine & Public Health Source Type: news